1tsm: Difference between revisions

Revision as of 12:46, 28 July 2008

This article has been automatically seeded. Changes to this page should pertain to the PDB entry only and not to the protein or biomolecule in general.

File:1tsm.png

Template:STRUCTURE 1tsm

L. CASEI THYMIDYLATE SYNTHASE WITH SPECIES SPECIFIC INHIBITORL. CASEI THYMIDYLATE SYNTHASE WITH SPECIES SPECIFIC INHIBITOR

Template:ABSTRACT PUBMED 9931028

About this StructureAbout this Structure

1TSM is a Single protein structure of sequence from Lactobacillus casei. Full crystallographic information is available from OCA.

ReferenceReference

Structure-based design of inhibitors specific for bacterial thymidylate synthase., Stout TJ, Tondi D, Rinaldi M, Barlocco D, Pecorari P, Santi DV, Kuntz ID, Stroud RM, Shoichet BK, Costi MP, Biochemistry. 1999 Feb 2;38(5):1607-17. PMID:9931028

Page seeded by OCA on Mon Jul 28 12:46:37 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-[[Image:1tsm.gif|left|200px]]
+{{Seed}}
+[[Image:1tsm.png|left|200px]]
 <!--
@@ Line 9: / Line 10: @@
 {{STRUCTURE_1tsm|  PDB=1tsm  |  SCENE=  }}
-'''L. CASEI THYMIDYLATE SYNTHASE WITH SPECIES SPECIFIC INHIBITOR'''
+===L. CASEI THYMIDYLATE SYNTHASE WITH SPECIES SPECIFIC INHIBITOR===
-==Overview==
+<!--
-Thymidylate synthase is an attractive target for antiproliferative drug design because of its key role in the synthesis of DNA. As such, the enzyme has been widely targeted for anticancer applications. In principle, TS should also be a good target for drugs used to fight infectious disease. In practice, TS is highly conserved across species, and it has proven to be difficult to develop inhibitors that are selective for microbial TS enzymes over the human enzyme. Using the structure of TS from Lactobacillus casei in complex with the nonsubstrate analogue phenolphthalein, inhibitors were designed to take advantage of features of the bacterial enzyme that differ from those of the human enzyme. Upon synthesis and testing, these inhibitors were found to be up to 40-fold selective for the bacterial enzyme over the human enzyme. The crystal structures of two of these inhibitors in complex with TS suggested the design of further compounds. Subsequent synthesis and testing showed that these second-round compounds inhibit the bacterial enzyme at sub-micromolar concentrations, while the human enzyme was not inhibited at detectable levels (selectivities of 100-1000-fold or greater). Although these inhibitors share chemical similarities, X-ray crystal structures reveal that the analogues bind to the enzyme in substantially different orientations. Site-directed mutagenesis experiments suggest that the individual inhibitors may adopt multiple configurations in their complexes with TS.
+The line below this paragraph, {{ABSTRACT_PUBMED_9931028}}, adds the Publication Abstract to the page
+(as it appears on PubMed at http://www.pubmed.gov), where 9931028 is the PubMed ID number.
+-->
+{{ABSTRACT_PUBMED_9931028}}
 ==About this Structure==
@@ Line 29: / Line 33: @@
 [[Category: Species specificity]]
 [[Category: Structure-based drug design]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 10:19:04 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 12:46:37 2008''